PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20687301-0 2009 The effect of simvastatin on mRNA expression of transforming growth factor-beta1, bone morphogenetic protein-2 and vascular endothelial growth factor in tooth extraction socket. Simvastatin 14-25 transforming growth factor, beta 1 Rattus norvegicus 48-80 27478339-12 2016 Connective tissue growth factor (CTGF) and transforming growth factor (TGF)-beta1 gene expression decreased significantly in the simvastatin group compared to the control group (P < 0.001). Simvastatin 129-140 transforming growth factor, beta 1 Rattus norvegicus 43-81 30233664-0 2018 Effect of simvastatin on expression of VEGF and TGF-beta1 in atherosclerotic animal model of type 2 diabetes mellitus. Simvastatin 10-21 transforming growth factor, beta 1 Rattus norvegicus 48-57 30233664-1 2018 Expression of vascular endothelial growth factor (VEGF) and transforming growth factor-beta1 (TGF-beta1) in atherosclerosis animal model of type 2 diabetes mellitus treated with simvastatin was investigated. Simvastatin 178-189 transforming growth factor, beta 1 Rattus norvegicus 94-103 30233664-14 2018 Simvastatin may play a therapeutic role in T2MD AS by downregulating VEGF and upregulating the expression of TGF-beta1. Simvastatin 0-11 transforming growth factor, beta 1 Rattus norvegicus 109-118 30056191-5 2018 RESULTS: Simvastatin decreased several factors enhanced by glucose excursions: circulating VEGF, mRNA TGF-beta expression in the myocardium and mRNA VEGFR-2 expression in the aorta. Simvastatin 9-20 transforming growth factor, beta 1 Rattus norvegicus 102-110 29201188-0 2017 Simvastatin augments activation of liver regeneration through attenuating transforming growth factor-beta1 induced-apoptosis in obstructive jaundice rats. Simvastatin 0-11 transforming growth factor, beta 1 Rattus norvegicus 74-106 29201188-8 2017 Furthermore, Sim-treated animals demonstrated significantly downregulated TGF-beta1 expression and improved liver function vs. the BDL+NS group, indicating a TGF-beta1 antagonizing function. Simvastatin 13-16 transforming growth factor, beta 1 Rattus norvegicus 74-83 29201188-8 2017 Furthermore, Sim-treated animals demonstrated significantly downregulated TGF-beta1 expression and improved liver function vs. the BDL+NS group, indicating a TGF-beta1 antagonizing function. Simvastatin 13-16 transforming growth factor, beta 1 Rattus norvegicus 158-167 29201188-11 2017 Moreover, analysis of TGF-beta1 signaling pathways demonstrated that there was an increased hepatic TGF-beta1 and Smad3 expression in the BDL group, which was attenuated in the presence of Sim. Simvastatin 189-192 transforming growth factor, beta 1 Rattus norvegicus 22-31 29201188-11 2017 Moreover, analysis of TGF-beta1 signaling pathways demonstrated that there was an increased hepatic TGF-beta1 and Smad3 expression in the BDL group, which was attenuated in the presence of Sim. Simvastatin 189-192 transforming growth factor, beta 1 Rattus norvegicus 100-109 29201188-13 2017 Sim displays hepatoprotective effects in liver cells via the upregulation of Smad7 expression and impaired TGF-beta signaling. Simvastatin 0-3 transforming growth factor, beta 1 Rattus norvegicus 107-115 27121011-0 2016 Simvastatin ameliorates ventricular remodeling via the TGF-beta1 signaling pathway in rats following myocardial infarction. Simvastatin 0-11 transforming growth factor, beta 1 Rattus norvegicus 55-64 27121011-7 2016 The results revealed that simvastatin significantly improved the hemodynamic indexes, left ventricular mass index, the myocardial tissue structure, the cardiomyocyte cross-sectional area and the collagen volume fraction, and also showed that the levels of TGF-beta1, TGF-activated kinase (TAK)1 and drosophila mothers against decapentaplegic (Smad)3 were significantly reduced following treatment with simvastatin, while the levels of Smad7 in the simvastatin treatment groups were markedly increased. Simvastatin 26-37 transforming growth factor, beta 1 Rattus norvegicus 256-265 24083846-2 2014 The aim of this study is to show and compare the actions of Simvastatin (Simv) and Erythropoietin (Epo) in renal expression of nuclear factor kappa B (NFkappaB), transforming growth factor-beta (TGF-beta), basic fibroblast growth factor (bFGF), platelet-derived growth factor B (PDGF-B), fibronectin and development of interstitial fibrosis in rats with unilateral ureteral obstruction (UUO). Simvastatin 60-71 transforming growth factor, beta 1 Rattus norvegicus 195-203 22890678-14 2013 Expression of TGF-beta1 by lymphocytes was markedly increased following treatment with high-dose simvastatin. Simvastatin 97-108 transforming growth factor, beta 1 Rattus norvegicus 14-23 21952298-2 2011 Since simvastatin has been proposed to decrease renal interstitial fibrosis, we hypothesized that the protective effect of statins was related to the expression of transforming growth factor-beta (TGF-beta) and type IV collagen (Col IV). Simvastatin 6-17 transforming growth factor, beta 1 Rattus norvegicus 197-205 21952298-6 2011 Simvastatin significantly inhibited HG-, AGE- or H(2)O(2)-induced expression of TGF-beta and Col IV (p < 0.05). Simvastatin 0-11 transforming growth factor, beta 1 Rattus norvegicus 80-88 21952298-7 2011 Moreover, simvastatin also inhibited HG-, AGE- and H(2)O(2)-induced activation of p38 mitogen-activated protein kinase, which indicated that the preventive effect of simvastatin on TGF-beta and Col IV may be associated with p38. Simvastatin 10-21 transforming growth factor, beta 1 Rattus norvegicus 181-189 21952298-7 2011 Moreover, simvastatin also inhibited HG-, AGE- and H(2)O(2)-induced activation of p38 mitogen-activated protein kinase, which indicated that the preventive effect of simvastatin on TGF-beta and Col IV may be associated with p38. Simvastatin 166-177 transforming growth factor, beta 1 Rattus norvegicus 181-189 21952298-8 2011 CONCLUSION: These findings suggest that simvastatin can reduce HG-, AGE- and H(2)O(2)-induced expression of TGF-beta and Col IV by inhibition of the p38 pathway. Simvastatin 40-51 transforming growth factor, beta 1 Rattus norvegicus 108-116 20024970-9 2010 Increased upregulation of TGF-beta1 was also observed in the simvastatin group on day 7 (p < 0.05) which was maintained until day 14. Simvastatin 61-72 transforming growth factor, beta 1 Rattus norvegicus 26-35 20024970-10 2010 These findings suggest that the proliferation and recruitment of osteoprogenitor cells were critical steps in early stage of bone healing and that these steps were enhanced by TGF-beta1 and BMP-2, which were stimulated by simvastatin. Simvastatin 222-233 transforming growth factor, beta 1 Rattus norvegicus 176-185 20687301-1 2009 AIM: To determine the effect of local simvastatin application on the mRNA expression level of transforming growth factor-beta1 (TGF-beta1), bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) in the tooth sockets of rat. Simvastatin 38-49 transforming growth factor, beta 1 Rattus norvegicus 94-126 20687301-1 2009 AIM: To determine the effect of local simvastatin application on the mRNA expression level of transforming growth factor-beta1 (TGF-beta1), bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) in the tooth sockets of rat. Simvastatin 38-49 transforming growth factor, beta 1 Rattus norvegicus 128-137 16320597-0 2005 [Effects of simvastatin on TGF-beta system of diabetic rat kidneys]. Simvastatin 12-23 transforming growth factor, beta 1 Rattus norvegicus 27-35 16320597-5 2005 Compared with the diabetic rat group, simvastatin could markedly decrease the mRNA and protein expression of TGF-beta1 and Tbeta II R (P < 0.05). Simvastatin 38-49 transforming growth factor, beta 1 Rattus norvegicus 109-118 18791746-4 2008 Anti-inflammatory effects of simvastatin were studied by evaluating the expression of the inflammatory mediators interleukin-1 beta (IL-1beta), transforming growth factor-beta1 (TGF-beta1), and transcription factor nuclear factor kappa B (NF-kappaB). Simvastatin 29-40 transforming growth factor, beta 1 Rattus norvegicus 178-187 18791746-6 2008 Simvastatin significantly decreases IL-1beta and TGF-beta1 expression and NF-kappaB activation, accompanied by significant attenuation of glomerulosclerosis and renal function at 12 weeks after ADR injection, and these changes occurred in the absence of lowering of serum lipids. Simvastatin 0-11 transforming growth factor, beta 1 Rattus norvegicus 49-58 18791746-8 2008 The beneficial effect of simvastatin might be mediated by the effect of anti-inflammatory action through a reduction of NF-kappaB activation, and IL-1beta and TGF-beta expression. Simvastatin 25-36 transforming growth factor, beta 1 Rattus norvegicus 159-167 15855201-17 2005 TGF-beta1, which was highly induced in the obstructed kidneys, decreased at the post-transcriptional level with SIMV treatment (5.35+/-0.75 vs 13.10+/-2.9 OD in VH, P<0.05). Simvastatin 112-116 transforming growth factor, beta 1 Rattus norvegicus 0-9 12846751-12 2003 Overexpression of TGF beta 1 and VEGF was observed in the glomeruli of diabetic rats and was attenuated by losartan, simvastatin, or the combination of both to a similar level. Simvastatin 117-128 transforming growth factor, beta 1 Rattus norvegicus 18-28